continuous wearable physiology (HRV, sleep, skin temperature, SpO2); Layer 3 (Year 2) adds cultural and dietary context that transforms generic biomarker interpretation into personalized intelligence; Layer 4 (Year 2) integrates the user's clinical history. The Day-1 product is Oria Foundational — a 9-marker wellness panel covering hydration, electrolytes, vitamins, ketones, microbiome indicators, and inflammatory baseline, positioned under FDA General Wellness Guidance for direct-to-consumer launch. From this foundation, the company expands through five product tiers over 2027–2029: women's hormonal health, men's androgen monitoring, GLP-1 and metabolic health, gut health, mental health, longevity, and Oria Sentinel — a CLIA-lab clinical pathway for early cancer surveillance. Fluid Medical is the Healthcare vertical of Fluid Scientific, a sovereign-data platform company headquartered in Vancouver, BC. First market launch is the United Arab Emirates (MOHAP wellness panel registration in progress), leveraging Federal Law No. 2 of 2019 to position the platform as the world's most credible jurisdiction for personal health data. US operations will run through a planned Delaware sub-entity (Fluid Precision Inc) for clinical pathways and ARPA-H contracting. Fluid Medical Ltd was incorporated in 2024 as the operating subsidiary of Fluid Scientific Development Limited (Vancouver, est. 2022). The company acquired the entirety of Vessel Health, Inc.'s intellectual property — patents, trademarks, and product technology — in February 2025 via a UCC foreclosure sale recorded with USPTO. Approximately US$1.9M of founder and Family & Friends capital has been deployed across the platform to date. The company is currently raising pre-seed capital and pursuing non-dilutive funding including ARPA-H FY26 SBIR/STTR (Topic 1, Women's Health Diagnostics), Hub71+ Life Sciences Cohort 20, and TAQADAM at KAUST.